Acumen Pharmaceuticals Inc. (ABOS) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, ABOS carries an RQD Score of 38 out of 100, a letter grade of D-, and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 7/20 (institutional accumulation and options positioning), Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

Taken together, the lowest-scoring pillars point to weak cash generation and weak signals of insider conviction. The fundamental pillar reflects a negative ROIC and a 0% FCF yield, meaning the company is not currently converting capital into free cash flow, a condition that typically places pressure on valuation and funding needs. The insider pillar's low score indicates limited evidence of insider conviction in the source flow. Institutional and options signals score modestly higher but do not offset the fundamental weakness. The forensic pillar sits at the midpoint of its range: a Piotroski F-Score of 2 out of 9 is weak, while an Altman Z-Score of 2.5 is not in itself a distress signal in this dataset, and Debt/Equity of 0.5 is moderate. Macro fit is neutral-to-weak with a Beta of 1.0, meaning the stock is assessed as moving in line with the broader market.

For a prospective investor evaluating the stock today, the principal upside driver would be a change in cash generation; the source data shows none yet. The principal valuation tradeoff is that the price of 0.21 and market capitalization of $165.6M reflect a stock that has fallen sharply, per the market data (-90.83%). The rating itself is a snapshot and is not a recommendation.

Per the SEC financials, the company reported no revenue and widening operating losses across the three periods, with net losses of $-52.4M, $-102.3M, and $-121.3M. Operating margin, gross margin, and net margin are each reported as 0% in the market data, and ROIC is -35%. Free cash flow was negative in every period. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, with Debt/Equity of 0.5. Reported cash rose from $35.6M to $54.0M, while debt is listed as N/A in the source data.

Recent news items from the source data are headlined as market wire reports, all tagged "YELLOW" for impact. One item, a Seeking Alpha report, carries the headline "Acumen Pharmaceuticals Stock: ALTITUDE-AD Failure Destroys The Investment Thesis (ABOS)," which is the most significant catalyst-related headline in the feed; the source data does not provide further detail on the trial. The remaining items are generic quote, price, and options-chain pages with no additional content. The Butterfly supply-chain graph reports no supply-chain linkages and no proprietary signals.

Risk watch items from the data include the reported negative free cash flow, the -90.83% price change, and the single failure-related headline. Not available in source data for any trial outcome details, guidance, or upcoming catalysts.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream dependencies, downstream customers, or sector correlation mapping.

• What did the ALTITUDE-AD study show, and how does that result affect the company's pipeline and cash runway?
• What products or programs generate or are expected to generate revenue, given reported revenue of $0.0M in each period?
• What is the reported debt balance, since the source data lists debt as N/A?
• Why do the TTM P/E and EPS remain unavailable when net losses are reported?
• What is the current cash runway given FY 2025 free cash flow of $-115.5M against year-end cash of $54.0M?